Shannon Thyme Klinger - 28 Feb 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Legal Officer
Signature
/s/ James Dillon, as Attorny-in-Fact
Issuer symbol
MRNA
Transactions as of
28 Feb 2025
Net transactions value
-$8,488
Form type
4
Filing time
03 Mar 2025, 16:46:16 UTC
Previous filing
28 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +233 +0.94% 24,968 28 Feb 2025 Direct F1
transaction MRNA Common Stock Tax liability $3,513 -113 -0.45% $31.09 24,855 28 Feb 2025 Direct F2
transaction MRNA Common Stock Options Exercise +329 +1.3% 25,184 28 Feb 2025 Direct F1
transaction MRNA Common Stock Tax liability $4,974 -160 -0.64% $31.09 25,024 28 Feb 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -233 -20% $0.000000 931 28 Feb 2025 Common Stock 233 Direct F1, F3
transaction MRNA Restricted Stock Units Options Exercise $0 -329 -11% $0.000000 2,630 28 Feb 2025 Common Stock 329 Direct F1, F4
transaction MRNA Stock Option (Right to Buy) Award $0 +55,543 $0.000000 55,543 01 Mar 2025 Common Stock 55,543 $30.96 Direct F5
transaction MRNA Restricted Stock Units Award $0 +34,655 $0.000000 34,655 01 Mar 2025 Common Stock 34,655 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F3 25% of the shares subject to this restricted stock unit award vested on March 1, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F4 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F5 25% of this option will vest and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
F6 25% of the shares subject to this restricted stock unit award will vest on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.